Clinical Results Sharing Scheduled for Baektoseotip-Paclitaxel Combination Therapy
[Asia Economy Reporter Eunmo Koo] MedPacto announced on the 4th that it plans to present the Phase 1b results of the combination therapy of Bactosertib and Paclitaxel at the European Society for Medical Oncology Virtual Congress 2020 (ESMO Virtual Congress 2020) this year. MedPacto plans to share the results exploring the safety and efficacy of Bactosertib combination therapy as a second-line treatment for metastatic adenocarcinoma patients at this conference.
MedPacto is conducting a clinical trial combining the anticancer drug candidate "Bactosertib," currently under development for gastric cancer patients, with the existing anticancer drug "Paclitaxel." This clinical trial is currently being conducted at six institutions, including Yonsei University Severance Hospital.
Paclitaxel, an anticancer drug currently prescribed to gastric cancer patients, has shown a progression-free survival period of 3 months when used as monotherapy and 4 months when combined with Ramucirumab, slightly extending survival. However, there is a demand for next-generation therapies to improve treatment outcomes for patients.
A MedPacto official stated, "According to the 2018 International Agency for Research on Cancer (IARC) data, gastric cancer ranks first worldwide in incidence among all cancers, making it a highly prevalent disease," adding, "If the combination of Paclitaxel and Bactosertib proves safety and superior treatment improvement effects compared to existing therapies, the demand for Bactosertib is expected to increase explosively."
Bactosertib is a drug candidate that inhibits the signaling of transforming growth factor-beta (TGF-β), which suppresses the therapeutic effects of immuno-oncology drugs. Bactosertib modulates the tumor microenvironment to enable immune cells to attack cancer cells, inhibits cancer stem cell formation and tumor angiogenesis, thereby addressing issues of drug resistance and inducing cancer cell death.
In particular, Bactosertib has the potential for indication expansion across all cancer types and can be combined with various cancer therapies. Currently, it is actively advancing as a global innovative drug with a total of 11 ongoing clinical trials, including those involving blockbuster drugs.
The European Society for Medical Oncology (ESMO 2020) is a prestigious oncology conference in the field of cancer research, attended by approximately 20,000 participants including global cancer researchers, oncology specialists, and pharmaceutical and biotech professionals. It serves as an academic platform for exchanging information on marketed and clinical anticancer drugs. This year, it will be held online for three days starting from the 19th of next month.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
